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Research
AbstrACt
Objectives The objective of this systematic review is to 
identify and summarise studies which examine epigenetic 
biomarkers in patients with Barrett’s oesophagus (BO) 
and their association with progression to oesophageal 
adenocarcinoma (OADC). BO is a precursor lesion for 
OADC. There is no clinical test to predict patients who 
are likely to progress to OADC. An epigenetic biomarker 
could predict patients who are at high risk of progression 
from BO to OADC which could facilitate earlier diagnosis 
and spare those unlikely to develop cancer from regular 
invasive surveillance endoscopy.
setting A systematic search was conducted of the 
following databases: MEDLINE, MEDLINE in Process, 
EMBASE, Cochrane Central, ISI Conference Proceedings 
Citation Index and the British Library’s ZETOC. Studies 
were conducted in secondary and tertiary care settings.
Participants All studies measuring epigenetic change 
in patients over 18 years old who progressed from non-
dysplastic BO to OADC were included. Genetic, in vitro 
and studies which did not measure progression in the 
same patient cohort were excluded. Study inclusion and 
risk of bias of individual eligible studies were assessed 
in duplicate by two reviewers using a modified Quality in 
Prognostic Studies tool.
results 14 studies met the inclusion criteria. 42 
epigenetic markers were identified, and 5 studies 
developed models aiming to predict progression to 
OADC.
Conclusions The evidence from this systematic review is 
suggestive of a role for p16 as an epigenetic biomarker for 
the progression of BO to OADC.
Prospero number CRD42016038654.
IntrOduCtIOn 
Barrett’s oesophagus (BO) is defined as 
an oesophagus in which any portion of the 
normal distal squamous epithelial lining is 
replaced by metaplastic columnar epithe-
lium which is clearly visible endoscopically 
(≥1 cm) above the gastro-oesophageal junc-
tion and confirmed histopathologically 
from oesophageal biopsies.1 BO arises due 
to long-standing gastro-oesophageal reflux 
disease (GORD) and chronic inflammation 
and is a precursor lesion for oesophageal 
adenocarcinoma (OADC) with progression 
through the metaplasia-dysplasia-carcinoma 
sequence.2 The likelihood of developing 
OADC is increased 1.7 times in patients with 
GORD, increasing to 10.6 times with BO.3 
The incidence of OADC has risen in parallel 
with increasing obesity and GORD in 
Western populations.4 Patients with OADC 
who are diagnosed at an early disease stage 
benefit from much improved 5-year survival 
rates of up to 39%5 in comparison to less 
than 13% with invasive late stage lesions,6 
highlighting the importance of early diag-
nosis and treatment.
Currently, there is no robust way of 
predicting which patients with BO will progress 
to OADC. Clinical and histological informa-
tion is currently the only tools at the clinician’s 
disposal to aid early detection of OADC. The 
British Society of Gastroenterology recom-
mends endoscopic surveillance of patients with 
BO, and the American College of Gastroenter-
ology endorses screening of high-risk patients 
for BO.1 7 Endoscopic surveillance is inva-
sive and expensive, and despite rigorous biopsy 
protocols, dysplasia and early cancers can be 
missed. A recent meta-analysis published in 
2012 demonstrated lower risk for progression 
strengths and limitations of this study
 ► Systematic review conducted following strict 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines. 
 ► Systematic and reproducible methodology using two 
independent reviewers.
 ► All mechanisms of epigenetic change included.
 ► Limited meta-analysis resulting from lack of stan-
dardisation between studies.
 ► Small patient numbers in the included studies.
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of non-dysplastic BO (NDBO) to OADC than previously 
reported with a pooled 0.33% (95% CI 0.28% to 0.38%) 
annual incidence of OADC in patients with NDBO.8 The 
annual incidence rate of OADC for patients with BO with 
high-grade dysplasia (HGD) is 7%–19%.9–11
Epigenetics is an emerging field which describes mech-
anisms of alteration of gene regulation and expression 
without changing the genetic code.12 The most widely 
recognised mechanisms of epigenetic change are covalent 
modifications and altered gene expression by non-coding 
RNAs. Covalent modifications alter the structure of DNA 
and include DNA methylation and histone modification.12 
Mechanisms of epigenetic change are discussed in more 
detail in the protocol for this systematic review.13
Epigenetic changes in ulcerative colitis (UC) are well 
described14–17 and have been shown to occur before 
neoplasia occurs at an early stage of UC-associated 
carcinogenesis.18 UC-associated carcinomas progress in a 
similar fashion to OADC as a result of chronic inflamma-
tion through the metaplasia-dysplasia-adenocarcinoma 
sequence.19 The Enhanced Neoplasia Detection and Cancer 
Prevention in Chronic Colitis trial is investigating whether 
a panel of methylated biomarkers detected in endoscopic 
biopsy samples can be used as a tool in conjunction with 
screening colonoscopy to help risk stratify patients who are 
at higher risk of progressing to carcinoma.20 In light of this, 
there is a need to consolidate the literature on epigenetic 
changes in Barrett’s carcinogenesis to determine if such 
changes provide a method of risk stratifying patients who 
are at risk of progression to OADC.
A scoping search was performed using MEDLINE, 
the Cochrane Library and internet sources to identify 
any systematic reviews or meta-analyses on epigenetic 
biomarkers in BO and oesophageal cancer (OC). Nine 
systematic reviews and meta-analyses were identified21–29 
which included mixed patient populations with OADC 
and oesophageal squamous cell carcinoma with only three 
reviews incorporating patients with BO.24 25 29 Seven reviews 
concentrated on a single type of epigenetic alteration with 
four investigating DNA methylation21–23 and three looking 
at micro RNA (miRNA) expression.25–27 The remaining two 
reviews investigated genetic alterations in progression of 
BO to OADC.28 29 No systematic reviews drawing together 
all aspects of epigenetic change within the field of Barrett’s 
carcinogenesis were identified.
AIm
To identify and summarise studies which examine 
epigenetic biomarkers in patients with BO and their 
association with progression to OADC.
methOds
Details of the methodology were registered on PROSPERO 
(CRD42016038654) and have also been published.13 A 
summary is reported here.
Patient and public involvement
This research question was developed to address the 
issue of BO surveillance. The priority for patients is early 
diagnosis of OADC and accurate surveillance. In order 
to achieve this, it is imperative that the correct patient 
group, that is, those who are at highest risk of progres-
sion to OADC, is placed under the most intensive of 
surveillance, and those at a lower risk can be spared such 
frequent invasive investigation. Epigenetic biomarkers 
may provide a robust way of risk stratifying patients for 
BO surveillance.
Patients and the public were not involved in the devel-
opment of this systematic review.
eligibility criteria
Any prospective and retrospective primary studies were 
eligible for inclusion provided they measured epigenetic 
markers in patients over the age of 18 years with BO. To 
be included, the study must have reported on progres-
sion from NDBO to BO with HGD or OADC in the same 
patient cohort. Relevant epigenetic markers are DNA 
methylation, histone modification, chromatin remod-
elling and micro and non-coding RNAs. Studies were 
excluded if they were case reports, narrative reviews, in 
vitro studies (eg, using cell lines), studies of genetic (rather 
than epigenetic) mutations, studies using biomarkers to 
predict a response to treatment (eg, chemotherapy) or 
animal studies.
search
A systematic search of the literature to the end of February 
2018 was undertaken. Text and index terms relating to 
the population (BO), the prognostic marker (epigenetic 
change) and the outcome (BO with HGD or OADC) were 
combined (see online supplementary appendix 1 for 
sample search strategy in MEDLINE). No study design, 
date or language restrictions were applied. MEDLINE, 
MEDLINE in Process, EMBASE, Cochrane Central, ISI 
Conference Proceedings Citation Index and the British 
Library’s ZETOC were searched from inception. Refer-
ence lists of identified studies and systematic reviews were 
screened for any additional relevant primary studies. 
Registers of clinical trials ( ClinicalTrials. gov and ICTRP) 
were searched for ongoing studies.
study selection
Two reviewers (TN and CLT) independently screened 
all titles and abstracts to identify potentially relevant 
studies using prespecified screening criteria. Full texts 
of potentially relevant articles were assessed against 
prespecified eligibility criteria. Eligibility was determined 
by two reviewers (TN and CLT) independently with any 
discrepancies resolved by discussion or referral to a third 
reviewer (OT).
data extraction
Data extraction of the included studies was carried out by 
one reviewer (TN) using a standardised data extraction 
form and checked independently by a second reviewer 
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(OT). Discrepancies were resolved by discussion or 
referral to a third reviewer (CLT and JD). Data were 
extracted on study design characteristics, patient charac-
teristics, prognostic marker and outcomes.
Quality assessment
The risk of bias of individual eligible studies was assessed 
in duplicate by two reviewers (TN and OT) using a modi-
fied Quality in Prognostic Studies tool.30 Risk of bias 
criteria was related to study participation (eg, method of 
sampling), study attrition, prognostic factor measurement 
and selection (eg, reliability of epigenetic technique and 
publication bias), outcome assessment (eg, undertaken 
in duplicate) and study confounding factors (measured 
and adjusted for). The main confounders are considered 
to be age, obesity, smoking and alcohol intake.1 Selected 
elements from prediction study risk of bias assessment 
tool (PROBAST)  which is currently under development 
(Wolff R) were used to assess the methodological quality 
of prognostic models in a similar fashion to Ensor et al’s 
2016 systematic review of prognostic models of venous 
thromboembolism31 including aspects on patient selec-
tion, statistical models used and model validation.
synthesis
Synthesis was narrative, with main findings tabulated. 
Studies were grouped by individual epigenetic marker 
or panel of markers. A lack of consistency in reported 
outcome metrics and heterogeneity relating to study 
design, length of follow-up, frequency of endoscopy 
and biopsy and experimental technique precluded any 
quantitative synthesis. Most studies presented results as 
percentage methylation or a ratio of differential meth-
ylation. Formal assessment of publication bias was not 
possible.
reporting
Reporting of this systematic review was according to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses32 guidelines (online supplementary 
appendix 2)
systemAtIC revIew results
Overall, 3995 records were screened, and 14 studies met 
the inclusion criteria (see figure 1 for study selection 
process and reasons for exclusion). The most common 
reasons for exclusion were lack of progression in the 
same population from NDBO to HGD or OADC, in vitro 
experimentation or no epigenetic change analysed in 
patient samples.
study characteristics
Table 1 shows the main study characteristics. All included 
studies were of a similar retrospective cohort design. In 
Figure 1 PRISMA 2009 flow diagram with reasons for exclusion. BO, Barrett’s oesophagus; HGD, high-grade dysplasia; 
NDBO, non-dysplastic Barrett’s oesophagus; OADC, oesophageal adenocarcinoma; OC, oesophageal cancer; OSCC, 
oesophageal squamous cell carcinoma; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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total, 12 of 14 studies reported patient numbers. A total 
of 404 patients were included. Two studies reported 
total lesions only (n=223). CpG promoter methylation 
was investigated in 13 studies and miRNA expression in 
one study.33 Forty-two unique epigenetic markers were 
reported. No studies investigated histone modification. 
Thirteen included studies analysed 38 differentially meth-
ylated CpG promoter sites, nine used methylation-spe-
cific PCR,34–42 two used methylight methylation-specific 
PCR,43 44 one used bisulfite pyrosequencing45 and one 
used methylation microarray techniques.46
Prognostic models
Five studies developed models aiming to predict progres-
sion to OADC (table 2).35 38–41 Three models included 
both epigenetic markers and clinical parameters.39–41
Schulmann et al39 performed a retrospective longitu-
dinal analysis of 53 patients contributing 106 specimens 
enrolled in a BO surveillance programme using Cox 
proportional hazards regression. Initially, 10 candidate 
prognostic marker genes were assessed using cross-sec-
tional data. Six of the genes (HPP1, TIMP3, APC, p16, 
CRBP1 and RUNX3) which demonstrated hypermethyla-
tion in patients with OADC and relative hypomethylation 
in normal oesophageal tissues were investigated in the 
longitudinal study. All except APC were associated with 
progression (HGD and OADC combined) in univariate 
analysis. A multivariate model including all six genes, 
age and segment length found evidence that HPP1, p16 
and RUNX3 were independently prognostic. The perfor-
mance of the full model (all eight covariates) was assessed 
by calculating the exponentiated multiplier of baseline 
hazard for covariates for each specimen (HR index). 
For specimens taken within 2 years of progression, the 
HR index was >5 in progressors compared with <5 in 
non-progressors. The authors report that the HR index 
was not predictive for specimens taken over 2 years before 
progression. The study reports OR but doesn’t explain 
how as the Cox model produces HRs. The authors note 
that the sample size is small, the study is retrospective, 
other potential clinical predictors were unavailable and 
the model uses a combined end point of HGD and OADC. 
In univariate analysis, TIMP3 had an OR for progression 
of 1.68 (95% CI 1.14 to 2.38) but this flipped to 0.5 (95% 
CI 0.22 to 1.04) in the multivariate analysis. The authors 
conclude that further validation of the markers (HPP1, 
p16 and RUNX3), ideally in prospective multicentre 
trials, is required.
Sato et al40 performed a retrospective cohort study 
on 62 patients providing a total of 118 specimens. They 
developed a model using linear discriminant analysis 
incorporating both clinical and epigenetic markers. 
Sex, BO segment length and histological diagnosis were 
combined with p16, HPP1 and RUNX3 CpG methylation 
status as well as a methylation index with a score of 0–3 
was considered. The best receiver operating character-
istic (ROC) curve for a 4-year follow-up in this cohort was 
Table 2 Models aiming to predict progression to OADC
Author/year Study type
Patient 
no (P:NP) Model used Result
Clément 
et al 200635
Retrospective 
cohort
28*
(12:16)
APC+TIMP3+TERT Hypermethylation in P versus NP (P 
81% vs NP 26% P<0.0001)
Jin et al 200941 Retrospective 
cohort
195*
(50:145)
Biomarker panel (p16, HPP1, RUNX3, 
CDH13, TAC1, NELL1, AKAP12, SST)
AUROC 0.72
Biomarker panel+age
(p16, HPP1, RUNX3, CDH13, TAC1, 
NELL1, AKAP12, SST)
AUROC 0.85
Sato et al 200840 Retrospective 
cohort
62
(28:34)
Methylation index (p16, HPP1, RUNX3) Hypermethylation in P versus NP
AUROC 0.75 (no CI stated)
Methylation index (p16, HPP1, 
RUNX3), segment length, pathology
AUROC 0.79
(95% CI 0.6968 to 0.8853)
Sensitivity 91.4
Specificity 51.8
Schulmann 
et al 200539
Retrospective 
cohort
53
(8:45)
Age, segment length, HPP1, TIMP3, 
APC, p16, CRBP1, RUNX3
HPP1, p16, RUNX3 independent risk 
factors in multivariate analyses
Model combined HR index >5 leads to 
an increased likelihood of progression 
within 2 years
Wang 
et al 200938
Retrospective 
cohort
57
(7:50)
P16+APC Hypermethylation of both APC and p16 
OR 14.97 (95% CI 1.73 to ∞, P=0.012) 
for neoplastic progression
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
AUROC, area under receiver operating characteristic; NP, non-progressing patients; OADC, oesophageal adenocarcinoma; P, progressing 
patients.
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generated using segment length, pathology and methyla-
tion index with an area under ROC (AUROC) of 0.7910 
(95% CI 0.6968 to 0.8853) with a specificity and sensitivity 
of 91.4% and 51.8%, respectively. Change in AUROC 
between this model and a model including predic-
tive markers alone was not assessed. Patient selection 
criteria were not reported, and the small sample size (62 
patients), the large number of possible parameter combi-
nations (n=127), and the cut-points for variables were 
chosen to optimise performance in this dataset results in 
a high level of uncertainly about the optimal parameter 
set. No external validation was performed.
Jin et al41 performed a double-blind multicentre case–
control study of 195 tissue specimens using an eight meth-
ylation biomarker panel of p16, HPP1, RUNX3, CDH13, 
TAC1, NELL1, AKAP12 and SST combined with patient 
age to predict which patients will progress to OADC. 
When assessed individually, p16, HPP1 and RUNX3 were 
associated with progression to OADC (P<0.05). When 
the panel of all eight markers was used compared with 
age alone as a predictor of progression, the increment 
in AUROC was 0.114 in a 4-year follow-up (0.630 age 
alone and 0.753 age+markers), demonstrating a clinically 
important improvement in the predictive power of the 
model within the dataset. This study compared clinical 
factors between progressor and non-progressor groups 
and found no significant difference in gender, body 
mass index (BMI), BO segment length, smoking status 
or alcohol consumption. External validation was not 
performed.
Clément et al35 performed a retrospective cohort study 
of 28 tissue specimens. Eighty-one per cent of patients 
(n=12) with combined hypermethylation of APC, TIMP3 
and TERT progressed to OADC compared with 26% of 
non-progressors (n=16) (P<0.0001). It was suggested that 
in combination, these three markers could be used to 
predict which patients are at higher risk of progression. 
No sensitivities or specificities were reported, and there 
was no ROC analysis. There is no indication of indepen-
dent prognostic value, and no internal or external valida-
tion was performed using this model.
Wang et al38 performed a retrospective cohort study 
on 7 progressor and 50 non-progressor patients. They 
reported that hypermethylation in both p16 and APC 
was a strong predictor of progression to dysplastic BO or 
OADC. Patients who were negative for both p16 and APC 
hypermethylation did not progress. Hypermethylation 
of both APC and p16 yielded an OR of 14.97 (95% CI 
1.73 to ∞, P=0.012) for subsequent progression to HGD 
or OADC. A limitation of this study is the short follow-up 
time of 4.1 years for the non-progressor group which 
may not be sufficient time for dysplasia or neoplasia to 
develop. The reported CI is extremely wide, making it 
difficult to accurately interpret the OR.
Individual markers analysed
Forty-two individual epigenetic markers were analysed 
in the 14 included studies. Ten studies investigated one 
or more of the following five individual markers: p16 
(CDKN2A), RUNX3, TIMP3, HPP1 and APC. Details of 
markers, assessment methods and findings can be found 
in tables 3–7. All five markers demonstrated CpG hyper-
methylation in patients who progressed from NDBO 
to OADC in at least one of the included studies. p16 (a 
tumour suppressor protein encoded by the CDKN2A 
gene) offered the most experimental data with 10 studies 
reporting on 220 progressor samples compared with 332 
non-progressor samples. Eight of the 10 studies demon-
strated a statistically significant difference in hypermeth-
ylation at p16.36 38–41 43–45 Barrett et al37 demonstrated 
CpG hypermethylation of CDKN2A in seven progressor 
samples of a specific genetic clonality; however, no control 
group was analysed in parallel for this specific marker in 
this study.
RUNX3 and HPP1 were analysed in four studies39–41 43 
as individual markers. Overall, 134 progressors and 234 
non-progressors were studied. Three studies39–41 demon-
strated statistically significant hypermethylation in both 
RUNX3 and HPP1 CpG sites in progressor samples; 
however, one study43 found no difference for either HPP1 
or RUNX3.
Three studies investigated TIMP3 CpG methyla-
tion35 39 44 (32 progressors and 69 non-progressors). One 
study showed a statistically significant difference in CpG 
hypermethylation between progressors and non-progres-
sors.35 One study showed significant hypermethylation 
and calculated an OR of 1.68 (95% CI 1.14 to 2.38) for 
progression on univariate analysis39; however, TIMP3 
could not be regarded as an independent risk factor as the 
OR dropped to 0.5 (95% CI 0.22 to 1.04) on multivariate 
analysis. The final study44 showed significantly increased 
TIMP3 methylation in non-dysplastic tissues of patients 
with associated dysplasia elsewhere in the oesophagus; 
however, there was no difference between progressors 
and non-progressors.
Three studies analysed APC35 38 39 (26 progressors and 
116 non-progressors). Wang et al38 demonstrated hyper-
methylation in progressors. Clément et al35 reported 
hypermethylation but did not provide any statistical 
analyses. Wang et al calculated an OR of 9 (95% CI 1.01 
to 88.52) for hypermethylation of APC in progressors. 
Conversely, Schulmann et al39 found no evidence of a 
difference (OR=1.00 (95% CI 0.59 to 1.33)) in progres-
sion with or without hypermethylation of APC. All three 
studies have similar sample size, study design and exper-
imental techniques. These contradictory findings with 
limited statistical validation and wide CIs call into ques-
tion the validity of APC as an epigenetic marker of BO 
progression.
The main methodological limitations across the studies 
were poor reporting of patient characteristics and study 
populations, including patient selection. There was little 
information about loss to follow-up, and it was often unclear 
exactly which samples were used and at which time-points 
in longitudinal analyses. There was limited blinding of 
researchers to the histology, and progressor status of the 
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Table 3 P16/CDKN2A
Author/year
Patient no 
(P:NP)
Experimental 
technique used
Methylation threshold 
definition
Statistical 
analysis Result
Barrett 
et al 199937
49 (39:6) Methylation-specific 
PCR
Positive or negative 
PCR on agarose gel
Not stated Seven progressor patients 
with specific genetic 
abnormality (LOH at 
17 p and 9 p) displayed 
hypermethylation at 
CDKN2A. No numerical 
value offered
Boerwinkel 
et al 201443
44 (48:10) Methylight 
methylation-specific 
PCR
Previously published 
cut-off values applied 
to raw MSP data to 
calculate frequency of 
hypermethylation: p16 
cut-off=0.02
Mann-Whitney 
test
Raw MSP values showed
Hypermethylated in P 
P<0.05
Clément 
et al 200635
28* (12:16) Methylation-specific 
PCR
Intensity of 
methylation-specific 
dot-blot assay 
compared
Not stated 0% P versus 12% NP 
methylated
No significant difference 
between P and NP
Eads 
et al 200144
20 (12:8) Methylight 
methylation-specific 
PCR
Intensity of methylated 
genes compared with 
controls. ‘PMR’ value 
of 4 used as cut-off to 
indicate methylated 
gene
Fisher’s PLSD Intensity of PCR band 
used for quantitative 
analysis
Hypermethylated in P 
P=0.0048
Jin et al 200941 195* (50:145) Methylation-specific 
PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
Student’s t test 
and chi-squared 
test
AUROC
NMVs P:NP
0.138:0.069
AUROC=0.628 (0.534, 
0.722)
90% sensitivity
90% specificity
Hypermethylated in P 
P=0.0066
Klump 
et al 199836
14 (10:4) Methylation-specific 
PCR
Yes/no detection of 
PCR product
Chi-squared test Hypermethylated in P
8% P versus 0% NP 
P=0.0001
Puertas 
Canteria 
201245
35 (6:14) Bisulfite 
pyrosequencing
Quantitative CpG 
methylation technique
No statistical 
analysis
Hypermethylated in P
Methylation grade 12.04% 
P versus 6.53% NP
Sato 
et al 200840
62 (28:34) Methylation-specific 
PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
LDA, LOOCV, 
AUROC
Hypermethylated in P
AUROC increment when 
added to segment length, 
histology and global 
methylation index=0.0335
90% sensitivity
90% specificity P=0.00576
Schulmann 
et al 200539
53 (8:45) Methylation-specific 
PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
Cox proportional 
HRs
Hypermethylated in P
OR 1.74
P=0.0005
Wang 
et al 200938
57 (7:50) Methylation-specific 
PCR
No threshold described OR using 
univariate logistic 
regression
Hypermethylated in P
OR 10.02 P=0.034
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
AUROC, area under receiver operating characteristic; LDA, linear discriminant analysis; LOH, Loss of Heterozygosity; LOOCV, leave-one-out 
cross-validation; MSP, methylation specific PCR; NMV, normalised methylation value; NP, non-progressing patients; P, progressing patients; 
PLSD, protected least significant difference; PMR, percent methylated reference.
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samples was often not described. Confounding factors 
were described in six of the studies,33 38–41 46 but only Sato 
et al40 adjusted for BO segment length and patient sex in 
their predictive model. Full details of quality assessment 
can be found in table 8.
Given these methodological uncertainties, the findings 
need to be viewed with caution.
dIsCussIOn
This systematic review of the literature of epigenetic 
markers and their role in predicting progression of BO 
to HGD and OADC has revealed a heterogeneous and 
disparate dataset. Fourteen studies were identified, with 
five incorporating prognostic models. This is the first 
systematic review to examine all evidence on epigenetic 
change and its role in Barrett’s carcinogenesis. It suggests 
a role for p16 hypermethylation as an individual epigen-
etic biomarker in predicting progression from BO to 
OADC.35–41 43–45 However, a paucity of evidence for other 
epigenetic markers (and combinations), poor reporting 
of patient characteristics and methods employed and lack 
of external model validation limit the conclusions that 
can be drawn.
Only 14 studies were identified with small patient 
numbers (median 31 (5–195)). The extent of loss to 
follow-up was usually poorly described. All studies 
suffered from a paucity of clinical information and a 
lack of reporting of study patient demographics. Those 
studies which did report comorbidities and potential 
confounding factors such as BMI, smoking status, age, 
histological diagnosis and BO segment length rarely 
adjusted for these in their analysis. Without adjusting 
for these factors, it is difficult to assess the incremental 
predictive clinical value of any epigenetic changes. 
Future models should explore the predictive ability 
of epigenetic changes in the context of clinical vari-
ables. In their study, Riley et al47 concluded that provi-
sion of individual patient data could have overcome 
the majority of the reporting issues including poorly 
reported summary statistics, adjustment factors and 
outcome measures used.
It is challenging to compare data from different 
studies due to variable measurement of epigenetic 
change. Five different experimental techniques were 
used: miRNA analysis (n=1)33 and CpG methylation 
including, methylation-specific PCR (n=9),48 methylight 
methylation-specific PCR (n=2),49 bisulfite pyrose-
quencing (n=1)45 50 and methylation microarray tech-
nology (n=1).46 Early methods of measuring differential 
DNA methylation involve semiquantitative reporting of 
results including analysis of intensity of PCR product 
bands on agarose gel. More advanced techniques use 
computerised photometry, although differing PCR 
conditions and equipment may result in variability 
Table 4 RUNX3
Author/year
Patient 
no 
(P:NP) Methods
Methylation threshold 
definition Statistical analysis Result
Boerwinkel 
et al 201443
44
(48:10)
Methylight 
methylation-
specific PCR
Previously published 
cut-off values applied 
to raw MSP data to 
calculate frequency 
of hypermethylation. 
RUNX3 cut-off=0.02
Mann-Whitney test Raw MSP values compared 
but no numerical value offered 
P versus NP not significantly 
differentially methylated
Jin et al 200941 195*
(50:145)
Methylation-
specific PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
Student’s t test and 
chi-squared test
AUROC
Hypermethylated in P
NMV 0.104:0.063
AUROC=0.671 (0.586, 0.756)
90% sensitivity
90% specificity P=0.0002
Sato et al 200840 62
(28:34)
Methylation-
specific PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
LDA, LOOCV, 
AUROC
Hypermethylated in P
AUROC increment when added 
to segment length, histology and 
global methylation index=0.0216
90% sensitivity
90% specificity P=0.016
Schulmann et al 
200539
53
(8:45)
Methylation-
specific PCR
NMV=amount of 
methylated DNA 
compared with control 
beta-actin DNA 
generated by PCR
Cox proportional 
HRs
Hypermethylated in P
OR=1.80 P=0.0267
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
AUROC, area under receiver operating characteristic; LDA, linear discriminant analysis; LOOCV, leave-one-out cross-validation; MSP, 
methylation specific PCR; NMV, normalised methylation value; NP, non-progressing patients; P, progressing patients. 
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between laboratories. More advanced techniques such 
as bisulfite pyrosequencing and methylation microar-
rays can provide an accurate methylation percentage 
at individual CpG sites which are suitable for quantita-
tive analysis. The 12 studies using methylation-specific 
PCR revealed a global pattern of hypermethylation of 
progressor patients in the CpG regions of interest34–44; 
however, each used differing methylation thresholds 
and outcome measures for reporting positive results. 
One study45 used bisulfite pyrosequencing to analyse 
p16, but no further markers were analysed on more 
than one platform. The different methods used, as well 
as the different outcome metrics reported and lack of 
clearly reported clinical information, meant that there 
Table 5 HPP1
Author/year
Patient 
no 
(P:NP) Methods Methylation threshold definition Statistical analysis Result
Boerwinkel et al 
201443
44
(48:10)
Methylight 
methylation-
specific PCR
Previously published cut-off 
values applied to raw MSP 
data to calculate frequency of 
hypermethylation. HPP1 cut-
off=0.05
Mann-Whitney test P versus NP 
not significantly 
differentially 
methylated
Jin et al 200941 195*
(50:145)
Methylation-
specific PCR
NMV=amount of methylated DNA 
compared with control beta-actin 
DNA generated by PCR
Student’s t test and 
chi-squared test
AUROC
Hypermethylated in P 
AUROC=0.647 (0.556, 
0.739) P=0.0025
Sato et al 200840 62
(28:34)
Methylation-
specific PCR
NMV=amount of methylated DNA 
compared with control beta-actin 
DNA generated by PCR
LDA, LOOCV, 
AUROC
Hypermethylated in 
P AUROC increment 
when added to 
segment length, 
histology and global 
methylation index
0.028
90% sensitivity
90% specificity 
P=0.018
Schulmann 
et al 200539
53
(8:45)
Methylation-
specific PCR
NMV=amount of methylated DNA 
compared with control beta-actin 
DNA generated by PCR
Cox proportional 
HRs
Hypermethylated in P
OR=1.77 P=0.0311
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
AUROC, area under receiver operating characteristic; LDA, linear discriminant analysis; LOOCV, leave-one-out cross-validation; MSP, 
Methylation Specific PCR; NP, non-progressing patients; P, progressing patients.
Table 6 TIMP3
Author/year
Patient 
no (P:NP) Methods
Methylation threshold 
definition Statistical analysis Result
Clément 
et al 200635
28*
(12:16)
Methylation-
specific PCR
Intensity of methylation-
specific dot-blot assay 
compared
Not stated Hypermethylated in P
% samples methylated
P=91%: NP=23% P<0.0001
Eads 
et al 200144
20
(12:8)
Methylight 
methylation-
specific PCR
Intensity of methylated 
genes compared with 
controls. ‘PMR’ value of 4 
used as cut-off to indicate 
methylated gene
Fisher’s PLSD Hypermethylated in non-
dysplastic tissue in patients 
with associated dysplasia; 
however, not statistically 
significant when comparing P 
versus NP P=0.13
Schulmann 
et al 200539
53
(8:45)
Methylation-
specific PCR
NMV=amount of methylated 
DNA compared with control 
beta-actin DNA generated 
by PCR
Cox proportional 
HRs
Hypermethylated in P, but 
not independent risk factor in 
multivariate analysis
OR=1.68 univariate
OR=0.50 multivariate 
P=0.0109
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
NP, non-progressing patients; P, progressing patients; PLSD, protected least significant difference; PMR, percent methylated reference.
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was insufficient clinical and methodological homoge-
neity. Meta-analysis was, thus, not appropriate, despite 
individual epigenetic markers being reported in up to 
10 independent studies.
Five models looked at various combinations of epigen-
etic markers and clinical risk factors. Findings from 
four of the models suggest a potential role for p16 in 
combination with HPP1, RUNX3 and/or APC and clin-
ical factors of segment length or age. All models used 
slightly different combinations of model parameters and 
reported analyses differently, thus making it difficult to 
compare findings between models. All suffered from a 
lack of external validation, and there were uncertainties 
around the representativeness of the included popula-
tions. More research is needed to validate and further 
explore these initial findings.
P16, a tumour suppressor protein, is the most consis-
tently hypermethylated CpG site in progressors. Hyper-
methylation leads to reduced p16 production, allowing 
neoplastic cells to progress from G1 to S phase of cell cycle 
and replicate uncontrollably. p16 deletions are observed 
in melanoma, oesophageal, lung, pancreatic, mesothe-
lioma, bladder, head and neck squamous cell carcinoma, 
breast, lymphocyte, brain, ovarian, osteosarcoma and 
renal cancer cell lines.51 52 In BO, p16 genetic mutations 
have been shown to occur early in tumorigenesis and may 
appear before dysplasia has occurred.53 Timmer et al54 
demonstrated the presence of p16, MYC and aneusomy 
in a model with age and segment length determined 
whether patients were at low or high risk of progres-
sion from NDBO to OADC. Without further in-depth 
temporal analysis, it remains unclear whether the index 
abnormality of Barrett’s carcinogenesis is epigenetic or 
genetic in origin.
The pattern of hypermethylation in RUNX3 and HPP1 
in progressors was less clear with not all studies demon-
strating a statistically significant difference between 
progressor and non-progressor patients. TIMP3 and 
APC provide variable results in the literature, and much 
smaller patient groups are analysed. Agarwal et al reported 
a predominance of hypomethylation in progressors (16 
of 19 CpG sites) with only three CpG sites (Pro_MMD2, 
Pro_ZNF358 and Intra_F10) hypermethylated. The meth-
ylation microarray used in this study can analyse 28 700 
unique CpG sites, whereas the latest technology offers 
up to 850 000 sites on a single chip.55 With only a single 
study using an outdated technique, it is not possible to say 
whether CpG hypomethylation is a driver in progressive 
BO. Prior to this technology being available, researchers 
had to carefully select CpG sites of interest for analysis; 
selection was based on previous research and literature 
review giving rise to a positive selection and publication 
bias. This is a well-recognised phenomenon in prog-
nostic factor research. Sekula et al56 reviewed published 
and unpublished work into p53’s role in bladder cancer 
and discovered that 31% of observational studies were 
unpublished in a 15-year period. While Sekula’s review 
is concerned with a different pathology, the type of 
included studies is of a similar design to those included 
in this review. A combination of positive publication 
bias and marker selection bias raises questions as to 
the validity of the selected markers in studies demon-
strating CpG hypermethylation. Selective reporting may 
also erroneously inflate the importance of individual 
prognostic markers. Kyzas et al57 analysed published 
and unpublished data sought directly from researchers 
investigating the importance of TP53’s role in head and 
neck squamous cell carcinoma on patient mortality. They 
found that if all published and unpublished data were 
included in their meta-analysis, the risk ratio decreased 
from 1.38 to 1.16 (95% CI 0.99 to 1.35 P=0.06). They also 
had difficulty conducting their analysis due to non-stan-
dardised definitions and reporting. Heterogeneity in 
definitions and reporting was also identified within our 
dataset, and it must also be considered whether selec-
tive reporting of results is over stating the importance 
of individual markers such as p16 in the progression of 
BO. Similarly, if ever increasing numbers of CpG sites 
Table 7 APC
Author/year
Patient 
no (P:NP) Methods
Methylation threshold 
definition Statistical analysis Result
Clément 
et al 200635
28*
(12:16)
Methylation-
specific PCR
Intensity of methylation-
specific dot-blot assay 
compared
No statistical 
analysis offered
Hypermethylated in P 
methylation:
P=100% versus NP=36%
Schulmann 
et al 200539
53
(8:45)
Methylation-
specific PCR
NMV=amount of methylated 
DNA compared with control 
beta-actin DNA generated 
by PCR
Cox proportional 
HRs
Hypermethylation not an 
independent risk factor for P
OR=1.00
(95% CI 0.59 to 1.33) P=0.99
Wang et al 
200938
57
(7:50)
Methylation-
specific PCR
No threshold described OR using univariate 
logistic regression
Hypermethylated in P 
methylation:
P=86% versus NP=40% 
P=0.02
OR=9 (1.01–80.52) P=0.049
*Number of lesions, no patient numbers described in the study; number of progressor lesions (P), number of non-progressor lesions (NP).
NP, non-progressing patients; P, progressing patients.
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are analysed with microarray technology, there will be 
an increasing number of negative results which are likely 
to be under-reported in the literature. As illustrated by 
Kyzas et al and Sekula et al,56 57 despite a large volume 
of literature, without standardisation of reporting and 
outcome measures, the research is often not suitable for 
translation into clinical use.
The variable quality of prognostic studies has been 
previously reported in systematic reviews58 59 and 
improvements suggested for collaboration and standard-
isation especially with regard to statistical analysis and 
outcome reporting.60–62 Poor quality of reporting was 
also a feature in this systematic review. For example, only 
7 of 14 included studies documented both the number 
of patients and samples analysed in each group. Stan-
dardised reporting of epigenetic studies in BO should 
provide basic clinical details for each patient including 
age, sex, smoking status, BMI and previous OC diagnosis 
and treatment. Each patient used in the study should 
have temporal information regarding OGD and biopsies 
taken, the number of biopsies, BO length, BO islands, 
hiatus hernia, visible lesions and classification of visible 
lesions documented according to the British Society of 
Gastroenterology (BSG) minimum endoscopic reporting 
dataset.1 In resection specimens, full histological reports 
should be available or at minimum staging tumour 
stage, nodal involvement, metastasis (TNM). It should 
be reported which patient samples have been used to 
perform epigenetic analysis and which methods of labo-
ratory analysis have been used. Clear reporting of statis-
tical analysis between cohorts must be provided to allow 
future meta-analysis of studies. Improved standardisation 
would make meta-analyses more feasible and lead to more 
informative systematic review results. This in turn would 
aid the translation of laboratory work into clinical trials.
COnClusIOn
The evidence from this systematic review is suggestive of 
a role for p16 as an individual epigenetic biomarker in 
predicting progression from BO to OADC. Prognostic 
models incorporating this and other markers also suggest 
a role for p16 in combination with HPP1, RUNX3 and/
or clinical markers. Further large primary studies using 
current epigenetic techniques and standardised reporting 
are required to inform future models to further explore 
the role of epigenetics in progression to HGD and OADC.
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